X4 Pharmaceuticals to Present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference

CAMBRIDGE, Mass., September 7, 2016 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference in New York on Friday, September 9, 2016 at 8:30 a.m. ET.

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases.  The company’s oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in immune surveillance.  X4P-001, the company’s lead program, is in Phase 1/2 testing in refractory clear cell renal cell carcinoma (ccRCC) and other solid tumor indications.  The company’s second program, X4P-002, is in pre-clinical development for oncology applications. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.


X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.